Today Vitrolife is publishing the Annual Report for 2013 in Swedish. The Annual
Report is attached to this press release and will also be available on (
The printed version of the Annual Report will be distributed by mail during the
week commencing 22 April. It will be distributed to Nordic shareholders who are
new from last year and to remaining shareholders who have requested that the
annual report should be sent to them.

The printed version of the Annual Report can be ordered on the company's website (, by phone +46 (0)31
721 80 00 or by email

Gothenburg, Sweden

April 11, 2014

Queries should be addressed to:

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on April
11, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.

Vitrolife ( is an international medical
device Group. Vitrolife Fertility (
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife ( has approximately 240
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share ( is
listed on NASDAQ OMX
Stockholm (
3469), Small Cap.


Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: Website: